CASC
AZN icon

Coppell Advisory Solutions Corp’s AstraZeneca AZN Stock Holding History

Coppell Advisory Solutions Corp’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-103
Closed -$14K – 263
2022
Q4 		$14K Buy
+103
New +$12.9K ﹤0.01% 556

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Coppell Advisory Solutions Corp's AZN Position: Q1 2023 in Review

Coppell Advisory Solutions Corp sold out of AstraZeneca (AZN) in Q1 2023, closing a stake of 103 shares — an estimated $14K sold.

Coppell Advisory Solutions Corp first reported a position in AZN in Q4 2022 and held it in 1 quarter. The position peaked at $14K in Q4 2022. 1,054 funds tracked by Wall St. Rank hold AZN as of Q1 2023.

  • Coppell Advisory Solutions Corp reported no remaining AstraZeneca position as of Q1 2023 after selling out during the quarter.
  • Coppell Advisory Solutions Corp sold 103 AstraZeneca shares in Q1 2023, an estimated $14K.
  • Coppell Advisory Solutions Corp first reported a position in AstraZeneca in Q4 2022 and held it in 1 quarter.
  • Coppell Advisory Solutions Corp's AstraZeneca position peaked at $14K in Q4 2022.
  • 1,054 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2023.

Based on Coppell Advisory Solutions Corp's 13F filing for Q1 2023, filed 10 May 2023.